Psoriasis: guselkumab shows good efficacy and safety in RCT meta-analysis

  • Yang J & al.
  • J Immunol Res
  • 1 Jan 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Guselkumab is associated with clinical efficacy and good tolerability for patients with moderate to severe plaque psoriasis, according to a systematic review and meta-analysis of 7 randomized controlled trials (RCTs).

Why this matters

  • This meta-analysis represents a comprehensive analysis of guselkumab to provide a basis for clinical application.

Key results

  • Guselkumab was associated with superior efficacy compared with placebo (ORs; 95% CIs):
    • ≥75 improvement in Psoriasis Area and Severity Index (PASI-75): 61.37 (31.15-120.91).
    • Investigator’s Global Assessment score of 0 or 1 (IGA 0/1): 65.75 (45.54-94.95).
    • Dermatology Life Quality Index score of 0 or 1 (DLQI 0/1): 29.64 (18.80-46.73).
  • Guselkumab also was associated with superior efficacy compared with adalimumab (ORs; 95% CIs):
    • PASI-75: 3.08 (2.35-4.06).
    • IGA 0/1: 2.79 (2.17-3.59).
    • DLQI 0/1: 1.86 (1.50-2.31).
  • Guselkumab was associated with a similar incidence of adverse events and infections compared with placebo and adalimumab.

Study design

  • Meta-analysis of 7 RCTs, including 1206 patients with plaque psoriasis treated with guselkumab, 1250 treated with adalimumab, and 585 who received placebo.
  • Funding: None disclosed.

Limitations

  • No long-term safety analysis.